Biotech RadarJobs updated

COMPANY

AIVITA Biomedical

HQ: Irvine, CA source · aivitabiomedical.com ↗ · West Coast

Clinical Phase 3

Personal Precision Immunotherapies WHO WE ARE AIVITA Biomedical is a biotechnology company developing personalized vaccines for the prevention of infectious disease and treatment of cancer. We take a pan-antigenic approach with our cancer vaccine — targeting all neoantigens, rather than a sel From company website Source · Oct 12, 2026

Keywords: cell therapy infectious disease stem cells vaccine COVID-19 Metastatic Melanoma Primary Glioblastoma Stage III Ovarian Carcinoma Stage IV Ovarian Carcinoma Fallopian Tube Carcinoma Primary Peritoneal Carcinoma Newly Diagnosed Glioblastoma retinal degeneration AV-COVID-19 AV-MEL-1 AV-GBM-1

Location: Irvine, CA · source · Aug 30, 2022

Profile checked Oct 10, 2026

7Trials (company is sponsor)1NIH grants

Timeline

  1. Trial start Phase 3: AV-GBM-1 vs Control as Adjunctive Therapy Following Surgery and RT/TMZ in Newly Diagnosed GBM source ↗
  2. Trial start I: Phase I-II Trial of Dendritic Cell Vaccine to Prevent COVID-19 in Adults source ↗
  3. Trial start Phase 1: Safety of AV-MEL-1 With Anti-PD-1 Therapy in Metastatic Melanoma source ↗
  4. Trial start Phase 2: Preventive Dendritic Cell Vaccine, AV-COVID-19, in Subjects Not Actively Infected With COVID-19 source ↗
  5. Trial start Phase 1: Dendritic Cell Vaccine, AV-COVID-19, to Prevent COVID-19 Infection source ↗
  6. Trial start Phase 2: Autologous Dendritic Cells Loaded With Autologous Tumor Associated Antigens for Treatment of Newly Diagnosed Glioblastoma source ↗
  7. Trial start Phase 2: Autologous Dendritic Cells Loaded With Autologous Tumor Associated Antigens for Treatment of Advanced Epithelial Ovarian Carcinomas source ↗

Upcoming milestones

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) 7

RecordTitlePhaseStatusStartPrimary completion
NCT04386252Phase I-II Trial of Dendritic Cell Vaccine to Prevent COVID-19 in AdultsIWithdrawn2023-012023-06 (estimated)
NCT03743298Safety of AV-MEL-1 With Anti-PD-1 Therapy in Metastatic MelanomaPhase 1Unknown status (ClinicalTrials.gov)Apr 21, 20212024-05 (estimated)
NCT05100641AV-GBM-1 vs Control as Adjunctive Therapy Following Surgery and RT/TMZ in Newly Diagnosed GBMPhase 3Not yet recruiting2024-012028-03 (estimated)
NCT02033616Autologous Dendritic Cells Loaded With Autologous Tumor Associated Antigens for Treatment of Advanced Epithelial Ovarian CarcinomasPhase 2Unknown status (ClinicalTrials.gov)Nov 18, 2017Mar 15, 2022 (actual)
NCT03400917Autologous Dendritic Cells Loaded With Autologous Tumor Associated Antigens for Treatment of Newly Diagnosed GlioblastomaPhase 2Unknown status (ClinicalTrials.gov)Jun 20, 2018Dec 1, 2021 (actual)
NCT04690387Dendritic Cell Vaccine, AV-COVID-19, to Prevent COVID-19 InfectionPhase 1CompletedDec 7, 2020Jan 13, 2021 (actual)
NCT05007496Preventive Dendritic Cell Vaccine, AV-COVID-19, in Subjects Not Actively Infected With COVID-19Phase 2CompletedApr 14, 2021May 31, 2021 (actual)

NIH awards 1

Annual award amounts. Total $280K.

Feedback